Patient characteristics at baseline
| Characteristics | n (%) |
|---|---|
| Age (years) | |
| < 55 | 20 (50.0) |
| ≥ 55 | 20 (50.0) |
| ECOG performance status | |
| 0 | 27 (67.5) |
| 1 | 13 (32.5) |
| Hormone receptor | |
| Negative | 20 (50.0) |
| Positive | 20 (50.0) |
| Histopathologic grade | |
| I–II | 18 (45.0) |
| III | 16 (40.0) |
| Unknown | 6 (15.0) |
| Tumor size (cm) | |
| ≤ 2.0 | 13 (32.5) |
| > 2.0 | 21 (52.5) |
| Unknown | 6 (15.0) |
| Axillary lymph node metastasis | |
| Positive | 29 (72.5) |
| Negative | 7 (17.5) |
| Unknown | 4 (10.0) |
| TNM stage at diagnosis | |
| I–II | 15 (37.5) |
| III | 18 (45.0) |
| Unknown | 7 (17.5) |
| Local recurrence | |
| Regional lymph node | 20 (50.0) |
| Chest wall | 17 (42.5) |
| Distant metastasis | |
| Distant lymph node | 20 (50.0) |
| Bone | 19 (47.5) |
| Lung | 13 (32.5) |
| Liver | 10 (25.0) |
| Pleura | 4 (10.0) |
| Skin | 3 (7.5) |
| Brain | 2 (5.0) |
| Metastasis ≥ 3 sites | 21 (52.5) |
| Starting dose of apatinib | |
| 425 mg | 23 (57.5) |
| 500 mg | 17 (42.5) |
| Lines of apatinib plus vinorelbine treatment | |
| < 3 line | 21 (52.5) |
| ≥ 3 line | 19 (47.5) |